PUBLISHER: Mordor Intelligence | PRODUCT CODE: 927854
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 927854
The Gemcitabine Hydrochloride Market is expected to register a CAGR of 7.1% during the forecast period. Growing research & development activities and growing burden of cancer diseases is expected to drive the gemcitabine hydrochloride market growth. According to World Health Organization, the incidence of cancer in 2018 was around 18.1 million worldwide. Furthermore, approximately 9.6 million of deaths occurred globally and Europe accounts for 20.3% of deaths. According to a study published in MDPI, in 2019, co-delivering technique in case of gemcitabine hydrochloride enhanced the survival rate in pancreatic patients. However, the rigorous regulatory framework for approvals of the product may impel the global gemcitabine hydrochloride market growth.
North America is expected to hold a major market share in the global gemcitabine hydrochloride market due to increasing burden of cancer diseases and advancement in product. Breast cancer is usually caused due to abnormal growth of cells in the tissues that are made up of glands (invasive) or in the ducts (in-situ). According to the American Cancer Society, Inc. in 2017, around 63,410 new cases were diagnosed in women in the United States. Moreover, approximately, 252,710 new cases were diagnosed with invasive breast cancer.
The Gemcitabine Hydrochloride Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Eli Lilly & Co., Accord Healthcare Inc., Pfizer Inc. (Hospira Inc.), Apotex Inc., Fressenius Kabi USA, Gland Pharma Ltd., Mylan Pharmaceuticals Inc., Sagent Pharmaceuticals Inc., Teva Pharmaceuticals Ltd. and JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD